Breaking Finance News

Motif Bio Plc (LON:MTFB) has been reiterated to Buy in a statement by Northland Capital earlier today.

Northland Capital has reiterated Motif Bio Plc (LON:MTFB) to Buy in a statement released on 11/15/2017.

On 10/31/2017, Peel Hunt released a statement for Motif Bio Plc (LON:MTFB) maintained the target price at 106.00GBX that suggested an upside of 1.55%.

Showing a price of 36.13GBX, Motif Bio Plc (LON:MTFB) traded -1.26% lower on the day. The last stock price is up 21.09% from the 200-day moving average, compared to the S&P 500 Index which has increased 0.02% over the date range. Motif Bio Plc has recorded a 50-day average of 37.03GBX and a two hundred day average of 32.41GBX. Trade Volume was down over the average, with 1,015,300 shares of MTFB changing hands under the typical 1,710,200

Recent Performance Chart

Motif Bio Plc (LON:MTFB)

Motif Bio Plc has with a one year low of 21.44GBX and a one year high of 52.00GBX and has a market capitalization of 0 GBX.

A total of 1 analyst has released a report on Motif Bio Plc. 1 firm rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of 114.00GBX.

About Motif Bio Plc (LON:MTFB)

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.